AVN-944


CAS No. : 297730-17-7

(Synonyms: VX-944)

297730-17-7
Price and Availability of CAS No. : 297730-17-7
Size Price Stock
1mg $68 In-stock
5mg $110 In-stock
10mg $170 In-stock
25mg $330 In-stock
50mg $495 In-stock
100mg $740 In-stock
200 mg Get quote
500 mg Get quote
We match the lowest price on market.

We offer a substantial discount on larger orders, please inquire via [email protected]

or Fax: (86)21-58955996

Inquiry for price and availability only. Please place your order via our email or fax.

Cat. No. : HY-13560
M.Wt: 477.51
Formula: C25H27N5O5
Purity: >98 %
Solubility: DMSO : 100 mg/mL (ultrasonic)
Introduction of 297730-17-7 :

AVN-944 (VX-944) is an orally active, potent, selective, noncompetitive and specific inhibitor of IMPDH (inosine monophosphate dehydrogenase). AVN-944 is an essential rate-limiting enzyme in de novo guanine nucleotide synthesis. AVN-944 is also an inhibitor of arenavirus RNA synthesis, and blocks arenavirus infection. AVN-944 has broad anti-cancer activities, and can be used for multiple myeloma (MM) and acute myeloid leukemia (AML) research[1][2][3]. In Vitro:AVN-944 (0-1 μM, 48 h) inhibits growth of human multiple myeloma (MM) cell lines in a dose-dependent manner[1].
AVN-944 (800 nM, 0-72 h) induces apoptosis in MM cell lines via a caspase-independent, Bax/AIF/Endo G pathway[1].
AVN-944 (0-200 nM) enhances the cytotoxicity of Doxorubicin (HY-15142A) and Melphalan (HY-17575)[1].
AVN-944 inhibits the proliferation of the human MV-4-11 and murine Ba/F3-Flt3-ITD-dependent cell lines with IC50 values of 26 and 30 nM, respectively[2].
AVN-944 (0-32 μM, 48 h) shows good activity against arenavirus infection at low doses (7.5 μM) with less cytotoxicity[3].
AVN-944 (0-6.4 μM, 48 h) does not reduce the viability of peripheral blood mononuclear cells (PBMNCs)[1]. In Vivo:AVN-944 (0-150 mg/kg, Orally, twice daily) significantly increases the median survival time of leukemia model mice[2].

Your information is safe with us.